Legislation in Connecticut that would have kept drug manufacturers from imposing “any preconditions, limitations, delays or other barriers” to 340B drug purchases “that are not required” by the 340B statute, died when this year’s legislative session ended on May 4.
SB 355 originally focused only on forbidding pharmacy benefit managers (PBMs) from discriminating against 340B covered entities and their contract pharmacies but was expanded later.
Legislation in Connecticut that would have kept drug manufacturers from imposing “any preconditions, limitations, delays or other barriers” to 340B drug purchases “that are not required” by the 340B statute, died when this year’s legislative session ended on May 4.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
